Iberdomide for Multiple Myeloma

Phase-Based Progress Estimates
Mayo Clinic in Rochester, Rochester, MN
Multiple Myeloma+2 More
Iberdomide - Drug
All Sexes
What conditions do you have?

Study Summary

This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving iberdomide in combination with daratumumab, bortezomib, and dexamethasone may kill more cancer cells in patients with newly diagnosed multiple myeloma.

Eligible Conditions

  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Multiple Myeloma

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: Up to 3 years

At the end of cycles 24 and 36
Proportion of patients who achieve sustained MRD negative status
Day 28
Proportion of patients with measurable residual disease (MRD) negative complete response (Phase II)
Year 3
Overall survival (Phase II)
Year 3
Progression-free survival (Phase II)
Day 28
Maximum tolerated dose (MTD) of iberdomide (Phase I)
Up to 3 years
Complete response rate (Phase II)
Minimal residual disease
Overall response rate (Phase II)
VGPR or better response rate (Phase II)
Day 30
Incidence of adverse events (AEs) (Phase II)

Trial Safety

Safety Progress

1 of 3

Other trials for Multiple Myeloma

Trial Design

1 Treatment Group

Treatment (iberdomide, bortezomib, dexamethasone, daratumumab)
1 of 1
Experimental Treatment

18 Total Participants · 1 Treatment Group

Primary Treatment: Iberdomide · No Placebo Group · Phase 1 & 2

Treatment (iberdomide, bortezomib, dexamethasone, daratumumab)Experimental Group · 4 Interventions: Iberdomide, Daratumumab, Dexamethasone, Bortezomib · Intervention Types: Drug, Biological, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 4
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years
Closest Location: Mayo Clinic in Rochester · Rochester, MN
Photo of Rochester 1Photo of Rochester 2Photo of Rochester 3
2021First Recorded Clinical Trial
23 TrialsResearching Multiple Myeloma
507 CompletedClinical Trials

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
12,930 Previous Clinical Trials
41,294,442 Total Patients Enrolled
553 Trials studying Multiple Myeloma
192,635 Patients Enrolled for Multiple Myeloma
Mayo ClinicLead Sponsor
2,860 Previous Clinical Trials
3,686,143 Total Patients Enrolled
68 Trials studying Multiple Myeloma
6,831 Patients Enrolled for Multiple Myeloma
Prashant KapoorPrincipal InvestigatorMayo Clinic in Rochester
2 Previous Clinical Trials
89 Total Patients Enrolled
2 Trials studying Multiple Myeloma
89 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have previously received no more than one cycle of any anti-myeloma treatment regimen.
Hemoglobin > 8.0 g/dL (obtained =< 14 days prior to registration).
You have a platelet count of at least 75,000/mm^3.
You have a total bilirubin level of < 1.5 x ULN.
You have received prior radiation therapy for the treatment of solitary plasmacytoma.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.